Injections of semaglutide were associated with significant improvement in cognitive function in people living with HIV (PWH), ...

Tecovirimat failed to reduce clade II mpox lesions, pain or viral clearance among participants in a study of the antiviral ...

Switching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and ...

Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Johnson's group demonstrated in a 2023 study that congenital syphilis is not more likely with a prenatal dose schedule using ...

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.

That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...